STAAR Surgical Company (STAA) Releases Earnings Results, Beats Expectations By $0.02 EPS

STAAR Surgical Company (STAA) reported quarterly earnings results on Wednesday, Aug-3-2016. The company said it had a profit of $-0.02 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.02. Analysts had a consensus of $-0.04. The company posted revenue of $20.97 million in the period, compared to analysts expectations of $19.91 million. The company’s revenue was up 12.4% compared to the same quarter last year.

Many Wall Street Analysts have commented on STAAR Surgical Company. The Benchmark Company Upgraded STAAR Surgical Company on May 18, 2016 to ” Buy”, Price Target of the shares are set at $6.

STAAR Surgical Company closed down -0.05 points or -0.72% at $6.87 with 54,689 shares getting traded on Tusday. Post opening the session at $6.92, the shares hit an intraday low of $6.66 and an intraday high of $7.0026 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.

In a different news, on May 23, 2016, Richard A Meier (director) sold 25,000 shares at $5.34 per share price. According to the SEC, on Aug 26, 2015, Caren L Mason (CEO) purchased 10,000 shares at $7.34 per share price. On Aug 11, 2015, Lou Silverman (director) purchased 1,500 shares at $8.18 per share price, according to the Form-4 filing with the securities and exchange commission.

STAAR Surgical Company designs develops manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The Company’s principal products are intraocular lenses (IOLs) and implantable Collamer lenses (ICLs). IOLs are prosthetic intraocular lenses used to restore vision that has been adversely affected by cataracts and include the Company’s lines of silicone and Collamer IOLs and the Preloaded Injector (a silicone or acrylic IOL preloaded into a single-use disposable injector). ICLs consisting of the Company’s ICL and Toric implantable collamer lenses (TICL) are intraocular lenses used to correct refractive conditions such as myopia (near-sightedness) hyperopia (far-sightedness) and astigmatism. The Company operates under the brands STAAR Visian Collamer CentraFLOW AquaPORT nanoFLEX nanoPOINT Epiphany and AquaFlow. Collamer is the brand name for its collagen copolymer lens material.

STAAR Surgical Company

Leave a Reply

STAAR Surgical Company - Is it time to Sell?

Top Brokerage Firms are advising their investors on STAAR Surgical Company. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.